Nazareth Martinez Shedden is Vice President, Finance at Atavistik Bio. She brings more than 20 years of biopharmaceutical finance experience, with deep expertise in financial planning and analysis, strategic business partnering, capital planning, and operational excellence.
Prior to joining Atavistik Bio, Nazareth served as Vice President, Strategic Finance at MOMA Therapeutics, where she led equity financing activities, financial planning and analysis, and partnered closely with executive leadership to support corporate strategy, business growth, and key operational initiatives.
Previously, Nazareth spent 15 years at Takeda, where she progressed through roles of increasing responsibility, ultimately serving as Head of R&D Finance. In this role, she led finance for the Neuroscience, Gastrointestinal, and Oncology therapeutic areas, overseeing an annual R&D portfolio encompassing more than 50 development programs. She also led a high-performing finance organization supporting research and development, global project teams, portfolio analytics, business development, and strategic planning. Earlier in her career, she was Senior Finance Manager at Millennium Pharmaceuticals, where she supported financial planning and analysis for oncology research and development.
Nazareth holds an MBA with a concentration in Finance from Northeastern University and a degree in Pharmacy from Kennedy University in Buenos Aires, Argentina.